Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

The Trump administration’s new vaccine advisers endorsed this fall's flu vaccines late last week, but only those that don't ...

ATLANTA (AP) — U.S. Health Secretary Robert F. Kennedy Jr.’s new vaccine advisory committee backed another option to protect ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine. What to know.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.